Bristol’s Baraclude Label Adds Boxed Warning On Use In HIV/HBV Co-Infection

Updated labeling recommends HIV antibody screening prior to use and reinforces that entecavir is not recommended for HIV/HBV co-infected patients not on highly active antiretroviral therapy.